Viatris Inc (VTRS)

Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA and an Investment Account
Sell

$11.55

Buy

$11.65

arrow-up$0.06 (+0.52%)

Prices updated at 13 Dec 2025, 00:36 EST
| Prices minimum 15 mins delay
|
Prices in USD
Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.
NASDAQ
arrow-down-1.69%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Most recent dividend payment

0.120
Cash Dividend
24 Nov 2025
04 Nov 2025
24 Nov 2025
15 Dec 2025

Total dividend yield

Dividend history and forecast data table

YearDividend per shareDividend growth (%)
20250.4800-
20240.4800-
20230.4800-
20220.48000.45
20210.3300-
2020--
2019--
2018--
2017--
2016--

Total dividend yield data table

Year
chevron-l-regular
chevron-r-regular
Dividend yield (%)Buyback yield (%)
20254.493.35
20243.861.67
20234.431.90
20224.31-
20212.44-
2020--
2019--
2018-6.60
2017--
2016--

Dividend per share

% of earnings paid to shareholders

Dividend per share data table

YearDividend per share
20250.4800
20240.4800
20230.4800
20220.4800
20210.3300
2020-
2019-
2018-
2017-
2016-

% of earnings paid to shareholders data table

YearPayout ratio (%)
2025-
2024-
202331.79
202271.21
2021-
2020-
2019-
2018-
2017-
2016-
Latest Financial Report as of 12 Dec 2025
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.